$荃信生物-B(02_老虎社区_美港股上老虎

$荃信生物-B(02509)$ 奥托奇拜单抗注射液（1类新药）已经拿到国家药监局受理，受理号CXSL2600263，自免管线再添重磅新品种，临床价值同赚钱潜力双双拉满，实力再上一层楼！

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

推荐
最新

暂无评论

热议股票

{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":537170084664976,"tweetId":"537170084664976","gmtCreate":1772164129022,"gmtModify":1772164356189,"author":{"id":4215846347868680,"idStr":"4215846347868680","authorId":4215846347868680,"authorIdStr":"4215846347868680","name":"九月168","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":1,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"title":"","html":"<html><head></head><body><p><a href=\"https://laohu8.com/S/02509\">$荃信生物-B(02509)$ </a> 奥托奇拜单抗注射液（1类新药）已经拿到国家药监局受理，受理号CXSL2600263，自免管线再添重磅新品种，临床价值同赚钱潜力双双拉满，实力再上一层楼！</p></body></html>","htmlText":"<html><head></head><body><p><a href=\"https://laohu8.com/S/02509\">$荃信生物-B(02509)$ </a> 奥托奇拜单抗注射液（1类新药）已经拿到国家药监局受理，受理号CXSL2600263，自免管线再添重磅新品种，临床价值同赚钱潜力双双拉满，实力再上一层楼！</p></body></html>","text":"$荃信生物-B(02509)$ 奥托奇拜单抗注射液（1类新药）已经拿到国家药监局受理，受理号CXSL2600263，自免管线再添重磅新品种，临床价值同赚钱潜力双双拉满，实力再上一层楼！","highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/537170084664976","repostId":0,"isVote":1,"tweetType":1,"viewCount":78,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":["02509"],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":152,"optionInvolvedFlag":false,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"hasMoreComment":false,"orderType":2}